Invivyd reports FY2023 net loss $198.6M; obtains EUA for PEMGARDA COVID-19 PrEP

Invivyd, Inc.

Net loss $198.6M ($1.81/share) vs $241.3M ($2.23/share) in 2022; R&D expenses $163.6M.
Cash & equivalents $200.6M as of Dec 31, 2023; expects runway into Q4 2024 (excl. PEMGARDA sales).
Received EUA on Mar 22, 2024 for PEMGARDA (pemivibart) for COVID-19 PrEP in immunocompromised patients.
Raised $40.5M in gross proceeds from ATM facility in Feb 2024 to strengthen balance sheet ahead of launch.
Nominated VYD2311 as next SARS-CoV-2 mAb candidate; expects streamlined FDA development pathway.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Invivyd, Inc. reported the year ended December 31, 2023 results: net income Net loss was $198.6 million for the year ended December 31, 2023, EPS Basic and diluted net loss per share was $1.81 for the year ended December 31, 2023.

Period: the year ended December 31, 2023
Net income: Net loss was $198.6 million for the year ended December 31, 2023
EPS: Basic and diluted net loss per share was $1.81 for the year ended December 31, 2023
Result: reported results

Exact text from the filing

Invivyd, Inc. (the "Company") issued a press release announcing its financial results for the year ended December 31, 2023

View on SEC.gov

1052 earnings releases filed in the last 30 days. Browse all earnings releases →

Invivyd, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-079597

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.